Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
V VARIOUS
V03 ALL OTHER THERAPEUTIC PRODUCTS
V03A ALL OTHER THERAPEUTIC PRODUCTS
V03AC Iron chelating agents
V03AC03 Deferasirox
D03669 Deferasirox (JAN/USAN/INN) <JP/US>
USP drug classification [BR:br08302]
Electrolytes/Minerals/Metals/Vitamins
Electrolyte/Mineral/Metal Modifiers
Deferasirox
D03669 Deferasirox (JAN/USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
3 Agents affecting metabolism
39 Other agents affecting metabolism
392 Antidotes
3929 Others
D03669 Deferasirox (JAN/USAN/INN)
Drug groups [BR:br08330]
Vitamin and mineral
DG01692 Chelator
DG01691 Iron chelator
D03669 Deferasirox
Metabolizing enzyme substrate
DG02924 UGT substrate
DG03183 UGT1A1 substrate
D03669 Deferasirox
DG03184 UGT1A3 substrate
D03669 Deferasirox
Metabolizing enzyme inhibitor
DG01634 CYP1A2 inhibitor
D03669 Deferasirox
DG01641 CYP2C8 inhibitor
D03669 Deferasirox
Metabolizing enzyme inducer
DG02853 CYP3A/CYP3A4 inducer
DG01635 CYP3A4 inducer
D03669 Deferasirox
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D03669
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D03669
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D03669
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D03669
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D03669